{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:46Z","timestamp":1793946526605,"version":"4.8.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eclinm.2026.104066","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:07:45Z","timestamp":1783782465000},"page":"104066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinicopathological, multimodal treatment, and survival patterns for men with breast cancer in England and Wales: a population-based cohort study"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-957X","authenticated-orcid":false,"given":"Jemma M.","family":"Boyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Withrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Blacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Delon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibby","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Verrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6516-8125","authenticated-orcid":false,"given":"David A.","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-69006-1","article-title":"Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021","volume":"14","author":"Barclay","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.104066_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103027","article-title":"Global, regional, and national burden of male breast cancer in 204 countries and territories: a systematic analysis from the global burden of disease study, 1990\u20132021","volume":"80","author":"Li","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104066_bib3","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.ejso.2022.06.004","article-title":"A systematic literature review of the management, oncological outcomes and psychosocial implications of male breast cancer","volume":"48","author":"Rutherford","year":"2022","journal-title":"Eur J Surg Oncol: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology"},{"issue":"16","key":"10.1016\/j.eclinm.2026.104066_bib4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of Male breast cancer: ASCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104066_bib5","series-title":"Early and Locally Advanced Breast Cancer: Diagnosis and Management","year":"2024"},{"key":"10.1016\/j.eclinm.2026.104066_bib6","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1245\/s10434-023-13475-7","article-title":"Axillary lymph node dissection is associated with improved survival among men with invasive breast cancer and sentinel node metastasis","volume":"30","author":"Chung","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/15579883221074818","article-title":"The prevalence and death risk of Male breast cancer: a study based on the surveillance, epidemiology, and end results database","volume":"16","author":"Cui","year":"2022","journal-title":"Am J Mens Health"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104066_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjsurg.2022.12.009","article-title":"Characteristics, treatment and outcomes of HER2 positive male breast cancer","volume":"225","author":"Esposito","year":"2023","journal-title":"Am J Surg"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104066_bib9","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/PAS.0000000000000749","article-title":"The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship","volume":"40","author":"Duggan","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/bjc.2011.168","article-title":"Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates","volume":"105","author":"M\u00f8ller","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35525","article-title":"Comparison of incident breast cancer cases in the largest national US tumor registries","volume":"131","author":"Plichta","year":"2025","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","article-title":"Breast carcinoma in men: a population-based study","volume":"101","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2026.104066_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2020.08.010","article-title":"Epidemiology of male breast cancer","volume":"54","author":"Konduri","year":"2020","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104066_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2009.23.8162","article-title":"Male breast cancer: a population-based comparison with female breast cancer","volume":"28","author":"Anderson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104066_bib15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jamaoncol.2019.2803","article-title":"Overall mortality after diagnosis of breast cancer in men vs women","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2026.104066_bib16","article-title":"Clinicopathologic features and radiation therapy utilization in patients with Male breast cancer: a national cancer database study","volume":"12","author":"Weir","year":"2018","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/curroncol30010023","article-title":"A prospective population-based study of cardiovascular disease mortality following treatment for breast cancer among men in the United States, 2000-2019","volume":"30","author":"Appiah","year":"2022","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104066_bib18","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1245\/s10434-012-2479-z","article-title":"Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the national cancer data base","volume":"19","author":"Greif","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2026.104066_bib19","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/cncr.34448","article-title":"Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer","volume":"128","author":"Leone","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104066_bib20","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1245\/s10434-021-09857-4","article-title":"Despite equivalent outcomes, men receive neoadjuvant chemotherapy less often than women for lymph node-positive breast cancer","volume":"28","author":"Cao","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eclinm.2026.104066_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.breast.2022.06.004","article-title":"The role of postoperative radiation therapy in stage I-III male breast cancer: a population-based study from the surveillance, epidemiology, and end results database","volume":"65","author":"Wu","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41598-021-04342-0","article-title":"Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer","volume":"12","author":"Yao","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104066_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cncr.26295","article-title":"Underascertainment of radiotherapy receipt in surveillance, epidemiology, and end results registry data","volume":"118","author":"Jagsi","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jclinepi.2005.06.002","article-title":"Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews","volume":"59","author":"Du","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104066_bib25","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/j.clon.2017.02.011","article-title":"Rapid analysis of outcomes using the systemic anti-cancer therapy (SACT) dataset","volume":"29","author":"Pathak","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104066_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102423","article-title":"Completeness of endocrine therapy information in the Primary Care Prescription Database (PCPD) and secondary care treatment datasets: a national population-based cohort study using routine healthcare data","volume":"86","author":"Gannon","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.eclinm.2026.104066_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102337","article-title":"Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England","volume":"83","author":"Gannon","year":"2023","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104066_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070699","article-title":"Cohort profile: radiotherapy dataset (RTDS) in England","volume":"13","author":"Sandhu","year":"2023","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104066_bib31","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/bjs.6930","article-title":"Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score","volume":"97","author":"Armitage","year":"2010","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104066_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035395","article-title":"Construction of the secondary care administrative records frailty (SCARF) index and validation on older women with operable invasive breast cancer in England and Wales: a cohort study","volume":"10","author":"Jauhari","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104066_bib33","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/j.clon.2023.05.016","article-title":"Variation in rates of post-mastectomy radiotherapy among women with early invasive breast cancer in England and Wales: a population-based cohort study","volume":"35","author":"Miller","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eclinm.2026.104066_bib34","series-title":"Understanding & Interpreting the Effects of Continuous Variables. The MCP (MarginsContPlot) Command","author":"Williams","year":"2023"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12874-022-01666-x","article-title":"Estimating causal effects in the presence of competing events using regression standardisation with the Stata command standsurv","volume":"22","author":"Syriopoulou","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials \u2013 a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2026.104066_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2021.01.008","article-title":"Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework","volume":"134","author":"Lee","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjsurg.2022.09.043","article-title":"Trends in surgery and survival for T1-T2 male breast cancer: a study from the National Cancer Database","volume":"225","author":"Singh","year":"2023","journal-title":"Am J Surg"},{"issue":"23","key":"10.1016\/j.eclinm.2026.104066_bib39","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104066_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/eurpub\/ckw070","article-title":"Socioeconomic inequalities in breast cancer incidence and mortality in Europe\u2014A systematic review and meta-analysis","volume":"26","author":"Lundqvist","year":"2016","journal-title":"Eur J Publ Health"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104066_bib41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.ede.0000129512.61698.03","article-title":"Socioeconomic risk factors for breast cancer: distinguishing Individual- and community-level effects","volume":"15","author":"Robert","year":"2004","journal-title":"Epidemiology"},{"issue":"24","key":"10.1016\/j.eclinm.2026.104066_bib42","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men","volume":"378","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104066_bib43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104066_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10549-021-06182-y","article-title":"Tumor subtypes and survival in male breast cancer","volume":"188","author":"Leone","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104066_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/modpathol.2011.174","article-title":"Molecular subtyping of male breast cancer by immunohistochemistry","volume":"25","author":"Kornegoor","year":"2012","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/his.12862","article-title":"The cancer genetics and pathology of male breast cancer","volume":"68","author":"Deb","year":"2016","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104066_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bjc.6603600","article-title":"Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review","volume":"96","author":"Hind","year":"2007","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104066_bib48","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/bjs.10885","article-title":"Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survival","volume":"105","author":"Ward","year":"2018","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104066_bib49","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1016\/j.clbc.2021.11.001","article-title":"Gender differences in recommended treatment decisions among breast cancer patients: a study using the national cancer database","volume":"22","author":"Shahi","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"18","key":"10.1016\/j.eclinm.2026.104066_bib51","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa2412225","article-title":"Ten-year survival after postmastectomy chest-wall irradiation in breast cancer","volume":"393","author":"Kunkler","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104066_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104537","article-title":"The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis on behalf of the Clinical Oncology Breast Cancer Group (COBCG)","volume":"204","author":"Colciago","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104066_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00432-017-2539-7","article-title":"Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer","volume":"144","author":"Eggemann","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104066_bib54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V","article-title":"Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996","volume":"85","author":"Goss","year":"1999","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104066_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.1114","article-title":"Use and effectiveness of adjuvant endocrine therapy for hormone receptor\u2013positive breast cancer in men","volume":"4","author":"Venigalla","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104066_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cncr.33899","article-title":"Adjuvant tamoxifen adherence in men with early-stage breast cancer","volume":"128","author":"Oke","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104066_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3747\/co.v17i5.631","article-title":"Endocrine therapy for male breast cancer: rates of toxicity and adherence","volume":"17","author":"Visram","year":"2010","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104066_bib58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104066_bib59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clbc.2017.03.005","article-title":"Hormone receptor-positive breast cancer has a worse prognosis in Male than in female patients","volume":"17","author":"Li","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104066_bib60","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/00031348231212588","article-title":"Is there a survival difference between Male and female breast cancer subtypes according to the prognostic staging system? A population-based cohort study","volume":"90","author":"Sanli","year":"2024","journal-title":"Am Surg"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104066_bib62","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1470-2045(22)00398-9","article-title":"Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study","volume":"23","author":"Aggarwal","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:42Z","timestamp":1793944002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"alternative-id":["S2589537026003196"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104066","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological, multimodal treatment, and survival patterns for men with breast cancer in England and Wales: a population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104066"}}